Nasal Drops in Children and Infants: Safety Considerations

Safety Concerns and Contraindications

• Topical vasoconstrictors, such as nasal drops containing imidazoline derivatives, should be used with care in children below 1 year of age due to the narrow margin between therapeutic and toxic doses, increasing the risk for cardiovascular and CNS side effects, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2
• Significant safety concerns exist for children under 6 years, with documented cases of fatalities associated with decongestants in OTC preparations, particularly in children under 1 year, according to the American Academy of Pediatrics 3, 4

Evidence of Harm

• Between 1969 and 2006, there were 54 documented fatalities associated with decongestants in children under 6 years, with 43 of these deaths occurring in infants under 1 year, as reported by the Centers for Disease Control and Prevention 3

Regulatory Guidance

• The FDA's Nonprescription Drugs and Pediatric Advisory Committees recommended that OTC medications used to treat cough and cold, including nasal decongestants, no longer be used for children below 6 years of age, as stated by the FDA 3, 5

Administration Recommendations

• If nasal drops must be used in older children, proper administration technique is crucial, with the Mygind position or Ragan position recommended for optimal delivery, according to the American Academy of Otolaryngology 6
• Short-term use only, no more than 3 days, is recommended to avoid rhinitis medicamentosa, as advised by the American College of Allergy, Asthma, and Immunology 2, 7